This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.
This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.
Efficacy of Voraxaze® has been evaluated in 4 multi-centre, compassionate use, single-arm, open label studies in patients with delayed MTX elimination. There was no head to head study conducted between these trials - each study was separate and conducted independent of each other.
Abbreviations: CrCl, creatinine clearance; MTX, methotrexate; sCr, serum creatinine; SD, standard deviation; ULN, upper limit of normal.
†Plasma MTX concentration >2 SD of the mean MTX excretion curve specific for the dose of MTX administered.
†† Patients with at least 1 post-Voraxaze® MTX concentration measured by high-performnance liguid chromatography (HPLC)
ΔPatients with safety data available for analysis in the 4 studies. ΔΔPatients with central MTX date.
Efficacy of Voraxaze® has been evaluated in 4 multi-centre, compassionate use, single-arm, open label studies in patients with delayed MTX elimination.
Clinically important reduction (CIR) in MTX concentration based on central MTX HPLC data.
Abbreviations: CIR, clinically important reductions; HPLC, high-performance liquid chromatography; MTX, methotrexate.
Efficacy of Voraxaze® has been evaluated in 4 multi-centre, compassionate use, single-arm, open label studies in patients with delayed MTX elimination.
Prospective study to assess the role of Voraxaze®, leucovorin, and thymidine in the management and outcome of patients with HDMTX-induced nephrotoxicity.
Development of grade ≥4 toxicity after Voraxaze® administration.
